Lugano response criteria: Definition, Uses, and Clinical Overview

Lugano response criteria Introduction (What it is)

Lugano response criteria are standardized rules used to describe how lymphoma responds to treatment.
They translate imaging and clinical findings into shared categories like complete response or progression.
They are commonly applied in Hodgkin lymphoma and many types of non-Hodgkin lymphoma.
They are often used with PET/CT and CT scans in routine care and clinical trials.

Why Lugano response criteria used (Purpose / benefits)

Cancer care relies on clear, consistent ways to answer a practical question: Is the disease improving, staying the same, or getting worse after treatment? In lymphoma, that question can be complex because disease can involve lymph nodes, bone marrow, spleen, and other organs, and because treatment can leave behind scar tissue that is not active cancer.

Lugano response criteria are used to solve several problems that arise in everyday oncology practice:

• Standardization across clinicians and centers. A radiologist, oncologist, and clinical trial team need to speak the same “response language,” especially when care is shared across hospitals.
• More consistent interpretation of imaging. Lymphoma response is commonly evaluated with FDG-PET (a scan that shows metabolic activity) and CT (a scan that shows size and anatomy). The criteria help interpret both types of information.
• Treatment evaluation over time. Lymphoma care often involves baseline imaging, follow-up scans during therapy (interim), and end-of-treatment assessment. Using the same framework supports meaningful comparisons.
• Support for clinical decision-making. While the criteria do not dictate what a person should do, response categories can inform discussions about continuing, modifying, or changing therapy, depending on the clinical context.
• Clinical trial consistency. Trials require reproducible endpoints. Lugano response criteria provide commonly accepted response definitions that make results easier to compare across studies.

In simple terms, Lugano response criteria help teams measure treatment effect using agreed-upon categories, so patients and clinicians can understand what the scans and clinical findings are showing over time.

Indications (When oncology clinicians use it)

Clinicians typically use Lugano response criteria in situations such as:

• Baseline staging and documentation of disease burden before lymphoma treatment begins
• Interim response assessment during systemic therapy (for example, after several cycles), when PET/CT is part of care
• End-of-treatment response assessment to determine the best overall response category
• Suspected relapse or progression, when new symptoms or imaging findings raise concern
• Clinical trial enrollment and follow-up, where standardized response definitions are required
• Comparison of therapies in multidisciplinary planning (medical oncology, radiation oncology, and hematology teams)
• When lymphoma is FDG-avid, meaning it typically shows up clearly on PET as metabolically active disease

Contraindications / when it’s NOT ideal

Lugano response criteria are designed primarily for lymphoma response assessment and may be less suitable in some situations, including:

• Non-lymphoma cancers (solid tumors) where other response frameworks are more commonly used
• Lymphoma subtypes or disease patterns where FDG-PET is less informative, making PET-based categorization less reliable; clinicians may rely more on CT and clinical findings in these cases
• When imaging quality or consistency is limited, such as different scan techniques across sites or significant motion artifact
• Conditions that can mimic lymphoma activity on PET, including infection, inflammation, recent surgery, or certain benign processes (these can increase FDG uptake and complicate interpretation)
• Very early post-treatment imaging, when treatment-related inflammation may temporarily increase uptake; timing is individualized and varies by clinician and case
• When response must be assessed primarily by symptoms or labs, such as certain scenarios involving bone marrow, blood counts, or organ function where imaging alone is insufficient

In these scenarios, clinicians may adapt the approach, incorporate additional tests (such as biopsy), or use alternative frameworks that better match the clinical question.

How it works (Mechanism / physiology)

Lugano response criteria are not a treatment and do not have a pharmacologic “mechanism of action.” Instead, they provide a clinical pathway for interpreting evidence of lymphoma activity—especially from imaging—within a standardized response vocabulary.

At a high level, they work by combining:

• Tumor biology and imaging behavior. Many lymphomas are FDG-avid, meaning active lymphoma cells often take up more FDG (a radiolabeled glucose analog) and appear brighter on PET. This reflects increased cellular metabolism, which is common in many cancers and inflammatory processes.
• Anatomic changes on CT. CT helps assess the size of lymph nodes and masses. A residual mass can persist after therapy due to scar tissue even when active lymphoma is gone, so size alone may not tell the whole story.
• Standardized visual scoring for PET. PET results are often interpreted using the Deauville 5-point scale, which compares uptake in suspected sites to reference tissues (commonly the mediastinum and liver). This helps reduce subjectivity when deciding whether uptake suggests active disease.

Onset and duration do not apply the way they would for a drug or procedure. The closest relevant concept is timing of assessment: response categories can change depending on when imaging is performed (baseline vs interim vs end-of-treatment) and what therapy has occurred in between. Reversibility also does not apply, but interpretation can evolve as new imaging, symptoms, or biopsy results become available.

Lugano response criteria Procedure overview (How it’s applied)

Lugano response criteria are not a single procedure performed on the body. They are a structured method clinicians use to apply imaging and clinical findings to response categories. A typical workflow looks like this:

1. Evaluation/exam
   The care team documents symptoms (such as fevers, night sweats, weight change), physical findings (like enlarged lymph nodes), and performance status.

2. Imaging/biopsy/labs
   Baseline studies often include PET/CT or CT, plus blood tests. A biopsy establishes the lymphoma diagnosis and subtype. Additional tests may assess bone marrow or organ involvement when indicated.

3. Staging
   The team determines disease extent (where lymphoma is located) using imaging and clinical data. This staging context is important because response is interpreted relative to baseline disease.

4. Treatment planning
   A plan is developed based on lymphoma subtype, stage, symptoms, patient factors, and goals of care. Planning may involve medical oncology/hematology and sometimes radiation oncology or surgical teams (for biopsy and select situations).

5. Intervention/therapy
   Treatment may include systemic therapy (such as chemotherapy, immunotherapy, targeted therapy), radiation therapy in selected cases, or other approaches depending on the lymphoma type and clinical scenario.

6. Response assessment
   Follow-up imaging is interpreted using Lugano response criteria to categorize response (commonly complete response, partial response, stable disease, or progressive disease). PET-based assessment is often central when the lymphoma is FDG-avid.

7. Follow-up/survivorship
   Ongoing monitoring may include clinic visits, symptom review, labs, and imaging when clinically appropriate. The intensity and frequency of follow-up varies by cancer type and stage, treatment, and institutional practice.

Types / variations

In practice, Lugano response criteria are applied with variations based on lymphoma biology, the imaging available, and the clinical question. Common “types” or use patterns include:

• PET-based assessment (FDG-avid lymphomas)
  Often uses the Deauville 5-point scale to judge metabolic response. This can be especially helpful when a mass remains on CT but may no longer be active lymphoma.

• CT-based assessment (when PET is not used or less informative)
  Relies more on changes in lesion size and the appearance of new sites of disease. This may be relevant when PET is unavailable, contraindicated, or less reliable for a given lymphoma subtype.

• Timepoint-based application

• Baseline (pre-treatment): documents initial disease burden
• Interim: evaluates early response during therapy
• End-of-treatment: defines the overall response category for that treatment course

• Post-treatment surveillance/concern for relapse: helps interpret new findings in context

• Routine clinical care vs clinical trials
  Trials may require stricter timing, consistent imaging technique, and centralized review to reduce variability, while routine care is individualized.

• Adult vs pediatric practice considerations
  The framework is used across age groups, but imaging choices and timing may differ based on clinical context, radiation exposure considerations, and institutional protocols.

Pros and cons

Pros:

• Provides a shared, standardized language for lymphoma response
• Helps integrate metabolic (PET) and anatomic (CT) information in a structured way
• Supports more consistent comparisons over time (baseline vs follow-up)
• Useful for multidisciplinary coordination and communication with patients
• Commonly accepted for clinical trials, improving comparability across studies
• Can help distinguish residual scar tissue vs active disease in many FDG-avid cases

Cons:

• Not equally informative for all lymphoma subtypes, especially when FDG uptake is variable
• PET findings can be confounded by inflammation or infection, sometimes requiring further evaluation
• Requires high-quality, standardized imaging for best consistency across timepoints
• Does not replace clinical judgment; symptoms, labs, and sometimes biopsy remain important
• Response categories may feel overly simplified compared with real-world complexity (mixed responses can occur)
• Interpretation can vary between readers, particularly in borderline cases, even with scoring systems

Aftercare & longevity

Because Lugano response criteria describe response rather than provide treatment, “aftercare and longevity” mainly relate to what happens after a response assessment and what influences longer-term outcomes.

Key factors that commonly affect what follow-up looks like and how durable a response may be include:

• Cancer type and stage. Lymphoma subtype (for example, indolent vs aggressive behavior) and stage at diagnosis influence typical response patterns and monitoring approaches. Varies by cancer type and stage.
• Tumor biology. Molecular features, growth rate, and FDG avidity can affect how disease appears on imaging and how confidently response can be interpreted.
• Treatment intensity and completion. The specific regimen, dose intensity, and whether therapy was completed as planned can influence response durability. What is appropriate varies by clinician and case.
• Comorbidities and overall health. Heart, lung, kidney, liver conditions, infections, and immune status can affect treatment tolerance and recovery.
• Supportive care and rehabilitation. Management of fatigue, nutrition challenges, neuropathy, mood symptoms, and deconditioning may shape quality of life during survivorship.
• Follow-up strategy and access to care. The schedule for visits, labs, and imaging is individualized. Access to hematology-oncology, radiology expertise, and survivorship resources can affect how quickly concerns are evaluated.
• Late and long-term effects. Some therapies have delayed effects that require monitoring over time; follow-up plans often reflect the treatments used.

In many settings, clinicians combine Lugano-based response assessment with symptom review, physical exams, and selected lab testing to create a practical, patient-centered follow-up plan.

Alternatives / comparisons

Lugano response criteria are one way to categorize lymphoma response, but they sit within a broader landscape of assessment and treatment choices. Common comparisons include:

• Clinical assessment alone vs imaging-based response assessment
  Symptoms and physical exams remain important, but they may not reliably reflect internal disease status. Imaging adds detail but can introduce uncertainty (for example, inflammatory uptake on PET).

• Biopsy confirmation vs imaging-based categorization
  Imaging can suggest relapse or persistent disease, but biopsy may be used when confirmation is needed—especially if the result would change management. The need for biopsy varies by clinician and case.

• PET-based vs CT-based approaches
  PET focuses on metabolic activity and is often valuable in FDG-avid lymphomas. CT focuses on size and anatomy and may be used when PET is not appropriate or available. Each has strengths and limitations.

• Response criteria frameworks in other cancers
  Solid tumors often use other standardized criteria (such as size-based systems). Lugano response criteria are lymphoma-focused and are not a universal tool for all cancer types.

• Observation/active surveillance vs immediate treatment change
  A borderline or uncertain imaging result may lead to closer monitoring rather than immediate change, depending on symptoms, risk factors, and overall context. This is individualized and varies by cancer type and stage.

• Standard care vs clinical trials
  Trials may specify exact imaging schedules and response definitions; standard care is often more flexible and tailored to patient circumstances.

Overall, Lugano response criteria are best viewed as a communication and classification tool that complements (not replaces) clinical evaluation and, when needed, pathology confirmation.

Lugano response criteria Common questions (FAQ)

Q: Does using Lugano response criteria change my treatment by itself?
Lugano response criteria describe what imaging and clinical data show about response. They do not automatically determine the next treatment step. Clinicians use the response category along with symptoms, lab results, and the lymphoma subtype to discuss options.

Q: Is the response assessment painful?
The criteria themselves are not a procedure and do not cause pain. Discomfort, if any, usually relates to the tests used for assessment, such as an IV placement for contrast CT or PET tracer injection. Some people find lying still during imaging uncomfortable, especially with back pain or anxiety.

Q: Do I need anesthesia or sedation for the scans used in Lugano response criteria?
Most adults do not need anesthesia for PET/CT or CT. Sedation may be considered for people who cannot stay still, have severe claustrophobia, or in some pediatric settings. The approach varies by facility and patient needs.

Q: Are Lugano response criteria “safe”?
The criteria are a way of interpreting results and do not carry direct risk. Safety considerations usually relate to the imaging: PET/CT and CT involve radiation exposure, and some CT scans use contrast that may not be suitable for everyone. Clinicians balance test benefits and risks based on the clinical situation.

Q: What side effects can happen from the tests used to apply these criteria?
PET imaging commonly uses an injected tracer and typically has minimal side effects. CT contrast can sometimes cause warmth, a metallic taste, or allergic-type reactions, and may be used cautiously in people with certain kidney issues. Imaging teams screen for risk factors before administering contrast.

Q: How long does response assessment take?
The imaging appointment length varies by test type and facility workflow, and reporting can take additional time. Some centers provide preliminary impressions quickly, while final reports may take longer. Timing is influenced by scheduling, scan complexity, and whether specialist review is needed.

Q: What do “complete response” and “partial response” mean in plain language?
In general terms, complete response means there is no convincing evidence of active lymphoma by the criteria used (often including PET findings in FDG-avid disease). Partial response means the lymphoma has improved but has not fully resolved by the defined measures. The exact meaning depends on whether PET-based or CT-based assessment is being used.

Q: Can inflammation or infection make the scan look worse even if lymphoma is improving?
Yes. FDG-PET detects metabolic activity, and inflammation or infection can also increase FDG uptake. This is one reason clinicians interpret results in context and may repeat imaging, check labs, review symptoms, or consider biopsy when the findings are unclear.

Q: Will this affect my ability to work, exercise, or do normal activities?
Lugano response criteria do not impose activity limits by themselves. Any limitations usually come from the underlying lymphoma, treatment side effects, or the logistics of scan days (fasting instructions, time at the imaging center). Activity guidance is individualized by the treating team.

Q: Does response assessment have implications for fertility?
The criteria themselves do not affect fertility. Fertility concerns in lymphoma care are usually related to treatment type and intensity, and the time available for fertility preservation discussions. Patients who have fertility questions often discuss them with oncology and reproductive specialists as early as feasible.